Related Experiment Video
Updated: May 29, 2025
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
5.8K
A Cure for Type 1 Diabetes: Are We There Yet?
Christopher Schaaf1, Lori Sussel1
1Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Center, Denver, Colorado, USA.
Diabetes Technology & Therapeutics
|February 6, 2025
Summary
Type 1 diabetes (T1D) research explores stem cell therapies and immunoisolation devices for a potential cure. Current stem cell treatments require immunosuppression, while encapsulation methods face challenges with cell survival and tissue response.
Area of Science:
- Endocrinology
- Immunology
- Regenerative Medicine
Background:
- Type 1 diabetes (T1D) affects millions, with insulin therapy as the current standard of care.
- Existing treatments like islet transplantation face limitations due to donor scarcity and immunosuppression requirements.
- The ultimate goal for T1D is a functional cure beyond managing symptoms.
Purpose of the Study:
- To review current and emerging therapeutic strategies for curing Type 1 diabetes.
- To evaluate the potential of stem cell-based therapies and immunoisolation technologies.
- To identify challenges and future directions in T1D cure research.
Main Methods:
- Review of current literature on Type 1 diabetes treatments.
- Analysis of stem cell-based approaches for beta-like cell generation.
- Evaluation of immunoisolation device technologies for transplantation.
- Assessment of early-stage immune therapies for T1D onset delay.
Main Results:
- Stem cell-based therapies show promise but currently necessitate immunosuppressant agents.
- Immunoisolation devices offer a non-immunosuppressive alternative but face issues with long-term cell viability and fibrotic encapsulation.
- Early immune interventions can delay T1D progression.
Conclusions:
- Stem cell-derived beta cells represent a promising avenue for a T1D cure.
- Overcoming immune rejection and ensuring long-term cell function are critical challenges.
- Continued research is essential to refine stem cell therapies and encapsulation technologies for successful T1D treatment.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
01:15Diabetes: Management and Pharmacotherapy
232
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
232
01:22Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
01:36Carbohydrate Metabolism
10.7K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.7K
01:15Diabetes: Symptoms, Diagnosis, and Complications
499
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
499
01:16Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141